患有多发性硬化症的老年人的神经认知结果:来自横截面队列的证据
María Bárbara Eizaguirre1, Lucas Nicolás Lapalma2, Natalia Ciufia1
1Working Group on Demyelinating Diseases (CUEM). Neurology Division, Dr. J.M. Ramos Mejia Hospital, Buenos Aires, Argentina; Buenos Aires University, School of Psychology, Research Institute in Psychology, Buenos Aires, Argentina.
Multiple sclerosis and related disorders
|December 12, 2025
概括
患有多发性硬化症 (MS) 的老年人比年轻人有更高的认知障碍 (CI) 率. 然而,增加的神经障碍,而不是年龄本身,预测MS患者的CI.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 临床医学 临床医学
背景情况:
- 多发性硬化症 (MS) 的衰老加剧了神经退行和生理变化,增加了认知障碍 (CI) 的风险.
- 患有多发性硬化症 (OPMS) 的老年人的认知特征仍然不够,特别是在拉丁美洲.
研究的目的:
- 为了确定OPMS中CI的流行率和特征.
- 为了比较OPMS和MS (YPMS) 的年轻人之间的CI.
- 为了确定CI的临床预测因素,评估年龄作为一个独立的因素.
主要方法:
- 一项对339名患有多发性硬化症 (PwMS) 的人进行的观察性,横截面研究,使用标准化神经心理测试 (BICAMS,BRNB).
- CI定义为在至少两个领域的性能≤-1.5 SD.
- 使用统计测试对OPMS (>50年) 和YPMS (18-50年) 进行比较;用于预测因子识别的后勤回归.
主要成果:
- 在OPMS (59%) 和YPMS (42.6%) 中,CI的患病率更高.
- 信息处理速度是受影响最大的领域;OPMS在所有领域表现较差.
- 更大的神经障碍 (EDSS) 预测了更高的CI风险 (OR=1.92),而高等教育是保护性的 (OR=0.82);年龄不是一个显著的预测因素.
结论:
- 与YPMS相比,OPMS的CI患病率和严重程度更高.
- 神经障碍是CI的重要预测因素,独立于时间年龄.
- 多发性硬化症评估和干预的临床策略需要适应人口老龄化.
相关概念视频
01:30Cognitive Development During Adulthood
745
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
745
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
175
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
175
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
208
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
208
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
181
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
181